WO2009100936A3 - Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung - Google Patents

Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung Download PDF

Info

Publication number
WO2009100936A3
WO2009100936A3 PCT/EP2009/001042 EP2009001042W WO2009100936A3 WO 2009100936 A3 WO2009100936 A3 WO 2009100936A3 EP 2009001042 W EP2009001042 W EP 2009001042W WO 2009100936 A3 WO2009100936 A3 WO 2009100936A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
pharmaceuticals
novel aromatic
fluoroglycoside derivatives
aromatic fluoroglycoside
Prior art date
Application number
PCT/EP2009/001042
Other languages
English (en)
French (fr)
Other versions
WO2009100936A2 (de
Inventor
Wendelin Frick
Heiner Glombik
Stefan Theis
Ralf Elvert
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to MX2010008051A priority Critical patent/MX2010008051A/es
Priority to CA2714110A priority patent/CA2714110A1/en
Priority to JP2010546266A priority patent/JP2011511820A/ja
Priority to BRPI0907572-0A priority patent/BRPI0907572A2/pt
Priority to CN2009801125891A priority patent/CN101998962A/zh
Priority to EP09711333A priority patent/EP2268653A2/de
Priority to AU2009214278A priority patent/AU2009214278A1/en
Publication of WO2009100936A2 publication Critical patent/WO2009100936A2/de
Publication of WO2009100936A3 publication Critical patent/WO2009100936A3/de
Priority to IL207201A priority patent/IL207201A0/en
Priority to US12/851,944 priority patent/US20110059910A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Neue aromatische Fluorglykosidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung. Die Erfindung betrifft aromatische Fluorglykosidderivate der Formel (I), worin die Reste die angegebenen Bedeutungen haben, sowie deren physiologisch verträglichen Salze und Verfahren zu deren Herstellung. Die Verbindungen eignen sich z.B. als Antidiabetika.
PCT/EP2009/001042 2008-02-13 2009-02-13 Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung WO2009100936A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2010008051A MX2010008051A (es) 2008-02-13 2009-02-13 Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
CA2714110A CA2714110A1 (en) 2008-02-13 2009-02-13 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof
JP2010546266A JP2011511820A (ja) 2008-02-13 2009-02-13 新規な芳香族フルオログリコシド誘導体、該化合物を含む薬剤及びその使用
BRPI0907572-0A BRPI0907572A2 (pt) 2008-02-13 2009-02-13 Derivados de fluorglicosídeos aromáticos, fármacos compreendendo os referidos compostos e uso dos mesmos
CN2009801125891A CN101998962A (zh) 2008-02-13 2009-02-13 新的芳香氟代糖苷衍生物,包含所述化合物的药物及其用途
EP09711333A EP2268653A2 (de) 2008-02-13 2009-02-13 Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2009214278A AU2009214278A1 (en) 2008-02-13 2009-02-13 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds, and the use thereof
IL207201A IL207201A0 (en) 2008-02-13 2010-07-25 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof
US12/851,944 US20110059910A1 (en) 2008-02-13 2010-08-06 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290152.1 2008-02-13
EP08290152 2008-02-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/851,944 Continuation US20110059910A1 (en) 2008-02-13 2010-08-06 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof

Publications (2)

Publication Number Publication Date
WO2009100936A2 WO2009100936A2 (de) 2009-08-20
WO2009100936A3 true WO2009100936A3 (de) 2009-10-22

Family

ID=39617750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/001042 WO2009100936A2 (de) 2008-02-13 2009-02-13 Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung

Country Status (15)

Country Link
US (1) US20110059910A1 (de)
EP (1) EP2268653A2 (de)
JP (1) JP2011511820A (de)
KR (1) KR20100121615A (de)
CN (1) CN101998962A (de)
AR (1) AR070701A1 (de)
AU (1) AU2009214278A1 (de)
BR (1) BRPI0907572A2 (de)
CA (1) CA2714110A1 (de)
CL (1) CL2009000309A1 (de)
IL (1) IL207201A0 (de)
MX (1) MX2010008051A (de)
TW (1) TW201000494A (de)
UY (1) UY31651A1 (de)
WO (1) WO2009100936A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8614195B2 (en) * 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015043511A1 (en) 2013-09-27 2015-04-02 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
WO2016041470A1 (en) * 2014-09-15 2016-03-24 National Institute Of Biological Sciences, Beijing Sglt-2 inhibitors
WO2018029264A1 (en) 2016-08-10 2018-02-15 Amneal Pharmaceuticals Company Gmbh Process for preparation of dapagliflozin and intermediates thereof
US10696662B2 (en) * 2017-08-21 2020-06-30 Janssen Pharmaceutica Nv 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
WO2019215633A1 (en) 2018-05-09 2019-11-14 Janssen Pharmaceutica Nv 5,5-difluoro- and 5-fluoro-5-methyl-c-glycoside derivatives useful as dual sglt1 / sglt2 modulators
CN109206331A (zh) * 2018-09-17 2019-01-15 康化（上海）新药研发有限公司 一种2-甲基丝氨酸的制备方法
CN113429379A (zh) * 2021-06-28 2021-09-24 江苏法安德医药科技有限公司 一种lh-1801中间体及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052902A1 (de) * 2002-12-12 2004-06-24 Aventis Pharma Deutschland Gmbh Neue aromatische fluorglycosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP1609785A1 (de) * 2003-03-14 2005-12-28 Astellas Pharma Inc. C-glycosidderivate und deren salze
WO2006037537A2 (de) * 2004-10-01 2006-04-13 Boehringer Ingelheim International Gmbh D-pyranosyl-substituierte phenyle, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2008013321A1 (en) * 2006-07-28 2008-01-31 Mitsubishi Tanabe Pharma Corporation Novel sglt inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2896397T5 (pl) * 2003-08-01 2023-06-19 Mitsubishi Tanabe Pharma Corporation Nowe związki mające działanie inhibitujące zależny od sodu transporter glukozy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052902A1 (de) * 2002-12-12 2004-06-24 Aventis Pharma Deutschland Gmbh Neue aromatische fluorglycosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP1609785A1 (de) * 2003-03-14 2005-12-28 Astellas Pharma Inc. C-glycosidderivate und deren salze
WO2006037537A2 (de) * 2004-10-01 2006-04-13 Boehringer Ingelheim International Gmbh D-pyranosyl-substituierte phenyle, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2008013321A1 (en) * 2006-07-28 2008-01-31 Mitsubishi Tanabe Pharma Corporation Novel sglt inhibitors

Also Published As

Publication number Publication date
EP2268653A2 (de) 2011-01-05
AR070701A1 (es) 2010-04-28
BRPI0907572A2 (pt) 2015-07-21
US20110059910A1 (en) 2011-03-10
CN101998962A (zh) 2011-03-30
CA2714110A1 (en) 2009-08-20
TW201000494A (en) 2010-01-01
WO2009100936A2 (de) 2009-08-20
AU2009214278A1 (en) 2009-08-20
IL207201A0 (en) 2010-12-30
KR20100121615A (ko) 2010-11-18
JP2011511820A (ja) 2011-04-14
CL2009000309A1 (es) 2009-06-26
MX2010008051A (es) 2010-08-10
UY31651A1 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
WO2009100936A3 (de) Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2007025709A3 (en) Organic compounds
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
MX2011005934A (es) Compuestos organicos.
MX2008014101A (es) Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
WO2007090749A3 (en) Benzamide and heteroarene derivatives as cetp inhibitors
WO2008083950A3 (de) Spirocyclische tetronsäure-derivative
UA98623C2 (ru) Соединения диосметина, способ их получения и фармацевтическая композиция, которая их содержит
WO2008080891A3 (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
WO2011009533A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10) -dien-11-ethinylphenyl-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
WO2008009750A3 (en) Macrocyclic compounds useful as bace inhibitors
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2007115929A8 (de) Thiazolyl-dihydro-quinazoline
WO2009024287A3 (de) Azoloarin derivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2007095021A3 (en) Novel compounds
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2009080745A3 (de) Perhydrochinoxalin-derivate als analgetika

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980112589.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09711333

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009711333

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/008051

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 207201

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009214278

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2714110

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4922/CHENP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107017950

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010546266

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PI 2010003309

Country of ref document: MY

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009214278

Country of ref document: AU

Date of ref document: 20090213

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0907572

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100812